David A. Frank, MD, PhD, FACP
-
RoleHematology
-
Specialty
-
Research Program
-
Practicing Since1993
Rating: 5 out of 5 (119 ratings)
David A. Frank, MD, PhD, FACP, is the director of the Division of Hematology and a professor in Emory University School of Medicine's Department of Hematology and Medical Oncology. He also serves as director of the Winship Innovation Initiative and as an advisor to the Morningside Center for Innovative and Affordable Medicine within the Woodruff Health Sciences Center. Board certified in medical oncology, he cares for patients with hematologic malignancies, specializing in leukemia. He is actively involved in training the next generation of clinical oncologists and cancer scientists.
Prior to joining Emory, Dr. Frank was the chief quality officer for Dana-Farber/Harvard Cancer Center, having previously served as chair of Quality Improvement for Medical Oncology, chair of the Pharmacy and Therapeutics Committee, and medical director of patient safety.
Dr. Frank received his MD and PhD from Yale University. After serving as an intern, resident, and chief resident in internal medicine at Yale, he completed training in medical oncology at Dana-Farber Cancer Institute, followed by a postdoctoral fellowship in intracellular signal transduction at Harvard Medical School.
A renowned physician-scientist, Dr. Frank's translational research laboratory focuses on the intracellular signaling pathways that control normal cellular function and become subverted in the development of cancer, and then using this knowledge in designing targeted molecular inhibitors for the treatment of cancer. His lab has developed innovative ways to target STAT transcription factors, leading to a series of therapeutic clinical trials, including the first clinical trial of a small molecule STAT3 inhibitor in cancer therapy.
Dr. Frank has authored or coauthored more than 100 peer-reviewed publications. He serves on the editorial board of Cancer Research, Clinical Cancer Research, and Cancer Biology and Therapy. In addition, he is an invited or ad hoc reviewer for several publications, including Blood, Nature Medicine, Science Signaling, Proceedings of the National Academy of Sciences, and others. PubMed
Dr. Frank is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute of Emory University. He is a Fellow of American College of Physicians. He holds professional memberships with American Association for the Advancement of Science, American Association of Cancer Research, American Society of Hematology, American Society of Clinical Oncology, and American Society for Microbiology. He serves as chair for the Medical Sciences Section of the American Association for the Advancement of Science.
| Title/Journal | Authors | Publication Date |
|---|---|---|
|
Experimental hematology |
B Rivera-Peña, S Chakraborty, Y Shi, H Zhang, SR Desai, PP Patel, Y Sun, R Zhao, G Choudhary, SG Mitchell, K Pradhan, J Zhang, X Zhang, B Fu, R Lopez, I Tošić, S Aluri, C Schinke, M Wysota, Z King, A Varshavsky, J Feld, M Carbajal, N Ramachandra, A Verma, M Goldfinger, S Sidoli, DA Frank, Y Saunthararajah, A Shastri | 04/01/2026 |
|
Proceedings of the National Academy of Sciences of the United States of America |
A Chang, AN Pelletier, DJ McGuire, M Tsagiopoulou, M Karipidou, A Ayers, AMK Leal, MC Churnetski, CB O'Leary, JM Switchenko, C Davis, DA Frank, JL Koff, JB Cohen, RP Sekaly, K Stamatopoulos, CR Flowers, R Ahmed | 09/09/2025 |
|
Challenging the "Undruggable"─Targeting STAT3 but Identifying Potent TrkA-Targeted Inhibitors. Journal of medicinal chemistry |
P Iliev, C McCutcheon, TH Admas, A Reithmeier, M Lopez McDonald, A van Outryve, D Hanke, JI Brown, M Haraldsson, RA Toillon, DA Frank, BDG Page | 05/08/2025 |
|
Neoplasia (New York, N.Y.) |
Z King, SR Desai, DA Frank, A Shastri | 03/01/2025 |
|
Frontiers in immunology |
H Ozuna, D Bojja, S Partida-Sanchez, L Hall-Stoodley, A Amer, RD Britt, S Sheikh, DA Frank, W Wang, BY Kang, I Miralda, SL Durfey, BT Kopp | 01/01/2025 |
|
Dissecting Out a Rare Mutation, STAT: Features of STAT3-Mutant Myeloid Neoplasms. Clinical cancer research : an official journal of the American Association for Cancer Research |
MJ Hochman, DA Frank | 10/15/2024 |
|
Cancers |
W Wang, MC Lopez McDonald, R Hariprasad, T Hamilton, DA Frank | 03/31/2024 |
|
European journal of medicinal chemistry |
JI Brown, R Persaud, P Iliev, U Karmacharya, S Attarha, H Sahile, JE Olsen, D Hanke, T Idowu, DA Frank, A Frankel, KC Williams, BDG Page | 01/15/2024 |
|
Prolactin levels and breast cancer risk by tumor expression of prolactin-related markers. Breast cancer research : BCR |
CA Hathaway, MS Rice, LC Collins, D Chen, DA Frank, S Walker, CV Clevenger, RM Tamimi, SS Tworoger, SE Hankinson | 03/07/2023 |
|
Clinical cancer research : an official journal of the American Association for Cancer Research |
EC Chen, H Gandler, I Tošić, GG Fell, A Fiore, O Pozdnyakova, DJ DeAngelo, I Galinsky, MR Luskin, M Wadleigh, ES Winer, R Leonard, K O'Day, A de Jonge, D Neuberg, AT Look, RM Stone, DA Frank, JS Garcia | 03/01/2023 |
|
Cycloguanil and Analogues Potently Target DHFR in Cancer Cells to Elicit Anti-Cancer Activity. Metabolites |
JI Brown, P Wang, AYL Wong, B Petrova, R Persaud, S Soukhtehzari, M Lopez McDonald, D Hanke, J Christensen, P Iliev, W Wang, DK Everton, KC Williams, DA Frank, N Kanarek, BDG Page | 01/19/2023 |
|
JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States. Cancer research |
LE Stevens, G Peluffo, X Qiu, D Temko, A Fassl, Z Li, A Trinh, M Seehawer, B Jovanović, M Alečković, CM Wilde, RC Geck, S Shu, NL Kingston, NW Harper, V Almendro, AL Pyke, SB Egri, M Papanastasiou, K Clement, N Zhou, S Walker, J Salas, SY Park, DA Frank, A Meissner, JD Jaffe, P Sicinski, A Toker, F Michor, HW Long, BA Overmoyer, K Polyak | 01/18/2023 |
|
Frontiers in immunology |
W Wang, MC Lopez McDonald, C Kim, M Ma, ZT Pan, C Kaufmann, DA Frank | 01/01/2023 |
|
Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer. Molecular oncology |
Y Yoshikawa, KH Stopsack, XV Wang, YH Chen, YZ Mazzu, F Burton, G Chakraborty, SH Rajanala, R Hirani, S Nandakumar, GM Lee, D Frank, E Davicioni, G Liu, MA Carducci, H Azuma, PW Kantoff, CJ Sweeney | 12/01/2022 |
|
Cell reports |
AK Ajay, L Zhao, S Vig, M Fujiwara, S Thakurela, S Jadhav, A Cho, IJ Chiu, Y Ding, K Ramachandran, A Mithal, A Bhatt, P Chaluvadi, MK Gupta, SI Shah, VS Sabbisetti, AM Waaga-Gasser, DA Frank, G Murugaiyan, JV Bonventre, LL Hsiao | 03/08/2022 |
|
The Journal of biological chemistry |
LN Heppler, S Attarha, R Persaud, JI Brown, P Wang, B Petrova, I Tošić, FB Burton, Y Flamand, SR Walker, JE Yeh, RA Zubarev, M Gaetani, N Kanarek, BDG Page, DA Frank | 02/01/2022 |
|
STAT3 as a mediator of oncogenic cellular metabolism: Pathogenic and therapeutic implications. Neoplasia (New York, N.Y.) |
I Tošić, DA Frank | 12/01/2021 |
|
Disease models & mechanisms |
L Wang, M Astone, SK Alam, Z Zhu, W Pei, DA Frank, SM Burgess, LH Hoeppner | 11/01/2021 |
|
Proceedings of the National Academy of Sciences of the United States of America |
F Valença-Pereira, Q Fang, IJ Marié, EL Giddings, KA Fortner, R Yang, AV Villarino, YH Huang, DA Frank, H Wen, DE Levy, M Rincon | 09/14/2021 |
|
British journal of cancer |
M Lapidot, AE Case, EL Weisberg, C Meng, SR Walker, S Garg, W Ni, K Podar, YP Hung, RD Carrasco, A Knott, PC Gokhale, S Sharma, A Pozhitkov, P Kulkarni, DA Frank, R Salgia, JD Griffin, SV Saladi, R Bueno, M Sattler | 08/01/2021 |
|
Inhibit versus Destroy: Are PROTAC Degraders the Solution to Targeting STAT3? Cancer cell |
LN Heppler, DA Frank | 11/11/2019 |
|
Targeting Oncogenic Transcription Factors: Therapeutic Implications of Endogenous STAT Inhibitors. Trends in cancer |
LN Heppler, DA Frank | 12/01/2017 |
|
ChemMedChem |
JE Yeh, DA Frank | 04/19/2016 |
|
Targeting BCL6 and STAT3 in triple negative breast cancer: the one-two punch? Oncoscience |
SR Walker, DA Frank | 01/01/2015 |
|
Annals of internal medicine |
DA Frank, J Marrazzo | 08/19/2014 |
|
STAT3 Activity and Function in Cancer: Modulation by STAT5 and miR-146b. Cancers |
SR Walker, M Xiang, DA Frank | 04/23/2014 |
|
Transcription factor STAT3 as a prognostic marker and therapeutic target in cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology |
DA Frank | 12/20/2013 |
|
Annals of internal medicine |
C Lathan, DA Frank | 11/19/2013 |
|
Targeting transcription factors: promising new strategies for cancer therapy. Current opinion in oncology |
JE Yeh, PA Toniolo, DA Frank | 11/01/2013 |
|
JAK2-STAT5 signaling: A novel mechanism of resistance to targeted PI3K/mTOR inhibition. JAK-STAT |
JE Yeh, PA Toniolo, DA Frank | 10/01/2013 |
|
Screening approaches to generating STAT inhibitors: Allowing the hits to identify the targets. JAK-STAT |
SR Walker, DA Frank | 10/01/2012 |
|
Targeting STATs for cancer therapy: "Undruggable" no more. JAK-STAT |
DA Frank | 10/01/2012 |
|
STAT signaling in the pathogenesis and treatment of myeloid malignancies. JAK-STAT |
M Bar-Natan, EA Nelson, M Xiang, DA Frank | 04/01/2012 |
|
Oncotarget |
EA Nelson, SV Sharma, J Settleman, DA Frank | 06/01/2011 |
|
STAT6 in PMBL: pathogenic or passenger? Blood |
DA Frank | 08/06/2009 |
|
Clinical cancer research : an official journal of the American Association for Cancer Research |
KM Sakamoto, DA Frank | 04/15/2009 |
|
Targeting transcription factors for cancer therapy. IDrugs : the investigational drugs journal |
DA Frank | 01/01/2009 |
|
ACP journal club |
DA Frank | 01/01/2008 |
Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.
| 5 |
| Provider showed concern |
| 5 |
| Provider explained things clearly |
| 4.9 |
| Provider discussed treatment options |
| 5 |
| Provider included you in decisions |
| 5 |
| Likelihood of recommending this provider |
|
04/25/2026 |
Dr. Frank provides excellent care and I have expressed my appreciation to him and I have told numerous people about him and the care I receive at Emory. |
|
04/16/2026 |
Dr. Frank is the best. |
|
04/09/2026 |
Very good doctor . |
|
03/19/2026 |
When I'm there in person they are very professional the doctor was able to pinpoint my problem on the first visit |
|
12/11/2025 |
Love Dr. Frank. Very thorough. |
|
12/05/2025 |
Good |
|
11/22/2025 |
Dr. Frank does an excellent job! He knows what he is doing and is sensitive to the patient's concerns. Great Doctor! |
|
11/20/2025 |
Dr Frank and his entire medical team are excellent. I feel like I am in the best hands possible |
|
10/23/2025 |
All the medical staff, including Dr. Frank, are very kind. |
|
10/16/2025 |
Dr Frank and Dr Kingsley were very kind and helpful. I am very relieved to have found this team and now have a little hope |
|
10/16/2025 |
Dr. Frank and team were wonderful, very informative and supportive |
|
10/05/2025 |
I feel confident under Dr. Frank's care. |
|
09/19/2025 |
Loved Dr. Frank and Dr. Nnawuba, as well as the nurse and tech who treated me. Very kind, professional and caring. |
|
09/11/2025 |
Dr. Frank is attentive and concerned about my health needs. |
|
09/11/2025 |
Dr. Frank has been attentive and has my complete trust as my doctor. He spends time listening to your concerns and thoroughly explains test results and next steps. I never feel rushed. I would highly recommend Dr. Frank to anyone who needs a top notch, passionate, understanding Hemotologist/Oncologist. |
|
09/04/2025 |
Dr. Frank is an excellent doctor. He listens to you and provides solutions to b address the issue. |
|
08/28/2025 |
Dr Frank was amazing, kind, thoughtful and thorough. |
|
08/14/2025 |
Dr Frank is a very kind and thoughtful doctor. |
|
06/23/2025 |
Dr. Frank spent time listening to my concerns and answered my questions. Very pleased with his suggestions and orders |
|
04/21/2025 |
Dr. Frank is always patient and takes plenty of time to let you ask questions. |
|
04/03/2025 |
Good. |
|
03/27/2025 |
Great |
|
11/02/2024 |
Dr. Frank and the team did an amazing job. They worked very well together and spent so much time explaining everything |
|
10/16/2024 |
Great first visit |
|
09/07/2024 |
Dr. Frank was good in appreciating my concerns. |
|
07/18/2024 |
Dr Frank is the best Dr I have ever seen. Competent, knowledgeable, kind, compassionate. He truly cares about his patients and has the vast knowledge to treat them effectively. |
|
05/30/2024 |
Dr. Frank was very easy to talk with and was good at answering my questions. |